Om

Opthea Limited is a clinical-stage biopharmaceutical company specializing in the development of biological therapies for serious eye diseases. Headquartered in Australia, Opthea focuses on targeting vascular endothelial growth factors VEGF-C, VEGF-D, and VEGF Receptor-3 to address conditions associated with abnormal blood and lymphatic vessel growth and vascular leakage. Its lead product candidate, sozinibercept (also known as OPT-302), is a novel VEGF-C/D “trap” biologic being evaluated in combination with existing anti-VEGF-A therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema. By aiming to complement standard treatments rather than replace them, Opthea is positioned within the biotechnology and healthcare sectors as a specialized developer of adjunctive ophthalmic therapies. The company’s activities span Australia and the United States, serving a global network of clinicians, research partners, and the broader biopharmaceutical ecosystem focused on retinal disease management.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I CERYVYN THERAPEUTICS MED ENDAVU: Køb Ceryvyn Therapeutics ($UKJ) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Ceryvyn Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.